Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?

J Clin Oncol. 2012 Nov 10;30(32):e341-4. doi: 10.1200/JCO.2012.43.1767. Epub 2012 Oct 1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / chemistry
  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / immunology
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy
  • Aged
  • Antigens, Surface / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood*
  • Biopsy / methods
  • Bone Neoplasms / secondary
  • Chemoradiotherapy
  • Disease Progression
  • Fatal Outcome
  • Glutamate Carboxypeptidase II / analysis
  • Humans
  • Liver Neoplasms / secondary
  • Lung Neoplasms / secondary
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / chemistry
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / immunology
  • Neoplasm Recurrence, Local / therapy
  • Neoplasm Staging
  • Phosphopyruvate Hydratase / blood
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Prostatectomy* / methods
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy
  • Radiotherapy Dosage
  • Receptors, Androgen / analysis
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antigens, Surface
  • Biomarkers, Tumor
  • Receptors, Androgen
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • Prostate-Specific Antigen
  • Phosphopyruvate Hydratase